高表达miR-3682-3p是肝细胞癌患者的不良预后因素

目的 分析miR-3682-3p在HCC中的表达及其与临床参数和预后的相关性。方法 生物信息学分析miR-3682-3p在HCC中的表达以及与生存相关性；实时荧光定量PCR和原位杂交分别检测miR-3682-3p（miR-3682）在18对HCC与癌旁新鲜肝组织以及90对石蜡包埋HCC及其癌旁组织中的表达差异。统计分析miR-3682-3p在HCC中的表达与患者临床参数和预后之间的关系。利用多因素回归分析探讨miR-3682-3p表达作为肝细胞癌预后独立因素的可能性。结果 生物信息分析显示，miR-3682-3p在HCC组织中高表达，且与HCC患者综合生存时间有统计学关联（χ2=8.793，P<0.001）。实时荧光定量PCR分析18组配对的HCC和癌旁肝组织显示，miR-3682-3p在癌组织中表达明显上调（t=3.073，P=0.007）。原位杂交分析90组配对的HCC和癌旁组织中miR-3682-3p的表达，显示其在癌与癌旁组织的细胞浆中表达，并且在癌组织中表达上调（t=2.659，P=0.009）。miR-3682-3p表达的高低在美国癌症联合委员会（AJCC）第八版分期（χ2=4.272，P=0.039）、HBV表面抗原状态（χ2=5.143，P= 0.023）、复发（χ2=4.593，P=0.032）、肿瘤大小（χ2=4.580，P=0.032）和Edmondson-Steiner分级（χ2=4.068，P=0.044）方面差异存在统计学意义；Kaplan-Meier分析显示，miR-3682-3p表达越高，患者总生存时间（Log rank χ2=4.169，P=0.041）和无病生存时间（Log rank χ2=4.078，P=0.043）越短。多变量分析显示，miR-3682-3p表达是评估HCC患者预后独立因子。结论 miR-3682-3p在HCC组织中表达上调，是促进HCC发病和预后不良的重要因子。

High expression of miR-3682-3p is an unfavorable prognostic factor of hepatocellular carcinoma

Objective To investigate the expression of miR-3682-3p in hepatocellular carcinoma (HCC) and its correlation with clinical parameters and prognosis of HCC. Methods We conducted a bioinformatics analysis of the expression of miR-3682-3p in HCC and its correlation with the patients' survival, and examined its expression in 18 pairs of fresh and 90 pairs of paraffin-embedded HCC and adjacent tissues using real-time fluorescence quantitative PCR and in situ hybridization, respectively. The correlation of miR-3682-3p expression in HCC with the clinical parameters and prognosis of the patients was analyzed. Multivariate regression analysis was used to explore the possibility of miR-3682-3p expression as an independent prognostic factor of HCC. Results Bioinformatics analysis showed that miR-3682-3p was highly expressed in HCC and significantly correlated with the survival time of HCC patients (χ2=8.793, P<0.001). The expression of miR-3682-3p was significantly up-regulated in fresh HCC tissues as compared with the adjacent liver tissues (t=3.073，P=0.007). In paraffin-embedded samples, in situ hybridization revealed positive miR-3682-3p expression in the cytoplasm of HCC and adjacent tissues, and its expression was signifcantly up-regulated in HCC tissues (t=2.659, P=0.009). The expression level of miR-3682-3p was significantly correlated with American Joint Commission on Cancer (AJCC; 8th edition) stage (χ2=4.272, P= 0.039), HBV surface antigen status (χ2=5.143, P=0.023), recurrence (χ2=4.593，P=0.032), tumor size (χ2=4.580, P=0.032) and Edmondson Steiner grade (χ2=4.068, P=0.044). Kaplan-Meier analysis showed that a higher expression of miR-3682-3p was associated with a shorter overall survival time (χ2=4.169, P=0.041) and disease-free survival time (χ2=4.078, P=0.043) of the patients. Multivariate analysis suggested that miR-3682-3p expression was an independent predictor of the prognosis of HCC patients. Conclusion MiR-3682-3p is up-regulated in HCC to serve as a significant factor that contributes to the occurrence and a poor prognosis of HCC.